ES2231826T3 - Anticuerpos monoclonales anti-cd6 para el tratamiento y el diagnostico de la psoriasis. - Google Patents

Anticuerpos monoclonales anti-cd6 para el tratamiento y el diagnostico de la psoriasis.

Info

Publication number
ES2231826T3
ES2231826T3 ES96939805T ES96939805T ES2231826T3 ES 2231826 T3 ES2231826 T3 ES 2231826T3 ES 96939805 T ES96939805 T ES 96939805T ES 96939805 T ES96939805 T ES 96939805T ES 2231826 T3 ES2231826 T3 ES 2231826T3
Authority
ES
Spain
Prior art keywords
psoriasis
monoclonal antibodies
diagnosis
treatment
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96939805T
Other languages
English (en)
Spanish (es)
Inventor
Casimiro Jose Enrique Montero
Valladares Josefa Lombardero
Rodriguez Rolando Perez
Blazquez Patricia Sierra
Bravo Blanca Rosa Tormo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Immunologia Molecular
Original Assignee
Centro de Immunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro de Immunologia Molecular filed Critical Centro de Immunologia Molecular
Application granted granted Critical
Publication of ES2231826T3 publication Critical patent/ES2231826T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES96939805T 1995-11-17 1996-11-18 Anticuerpos monoclonales anti-cd6 para el tratamiento y el diagnostico de la psoriasis. Expired - Lifetime ES2231826T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU1995120A CU22584A1 (es) 1995-11-17 1995-11-17 Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis

Publications (1)

Publication Number Publication Date
ES2231826T3 true ES2231826T3 (es) 2005-05-16

Family

ID=5459401

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96939805T Expired - Lifetime ES2231826T3 (es) 1995-11-17 1996-11-18 Anticuerpos monoclonales anti-cd6 para el tratamiento y el diagnostico de la psoriasis.

Country Status (15)

Country Link
US (1) US6572857B1 (enExample)
EP (1) EP0807125B1 (enExample)
JP (1) JP4113929B2 (enExample)
KR (1) KR100533854B1 (enExample)
CN (1) CN1222540C (enExample)
AT (1) ATE280783T1 (enExample)
AU (1) AU722882B2 (enExample)
BR (1) BRPI9607171B1 (enExample)
CA (1) CA2210751C (enExample)
CU (1) CU22584A1 (enExample)
DE (1) DE69633717T2 (enExample)
DK (1) DK0807125T3 (enExample)
ES (1) ES2231826T3 (enExample)
PT (1) PT807125E (enExample)
WO (1) WO1997019111A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1054316A1 (zh) * 2000-05-26 2003-11-28 Smithkline Beecham Corporation 用於治疗rank配体介导疾病的抗-rank配体单克隆抗体
CU23097A1 (es) 2002-10-23 2005-11-18 Centro Inmunologia Molecular Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método
US20040208890A1 (en) 2003-02-24 2004-10-21 Institut Pasteur Secreted chlamydia polypeptides, polynucleotides coding therefor, therapeutic and diagnostic uses thereof
EP2119453B1 (en) * 2006-12-26 2015-05-20 Centro de Inmunolgía Molecular Pharmaceutical compositions capable of inducing apoptosis in tumour cells, useful for diagnosis and treatment of b-chronic lymphocytic leukaemia
US20100092423A1 (en) 2006-12-26 2010-04-15 Centro De Inmunolgía Molecular Pharmaceutical composition comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis
HUE031207T2 (hu) 2008-01-11 2017-07-28 Adheron Therapeutics Inc Cadherin-11 EC1 domén elleni antitestek gyulladásos ízületi rendellenességek kezeléséhez
US8524233B2 (en) * 2008-03-14 2013-09-03 Biocon Limited & Centro de Immunologia Molecular Monoclonal antibody and a method thereof
CA2805112A1 (en) * 2010-07-15 2012-01-19 Synovex Corporation Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS63430B1 (sr) 2010-10-01 2022-08-31 Modernatx Inc Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
CN103782173B (zh) 2011-07-01 2018-07-13 贝克曼考尔特公司 调节t细胞和识别、获得、以及用于治疗基于免疫的紊乱的方法
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK3682905T3 (da) 2011-10-03 2022-02-28 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
DE12858350T1 (de) 2011-12-16 2021-10-07 Modernatx, Inc. Modifizierte mrna zusammensetzungen
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
HK1206601A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
FR3000216B1 (fr) * 2012-12-21 2015-02-06 Galderma Res & Dev Utilisation de proteases particulieres pour la detection de trichophytons et de pathologies associees
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
PT3024485T (pt) 2013-07-23 2021-01-25 Biocon Ltd Utilização de um parceiro de ligação de cd6 e método baseado no mesmo
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CN105504062B (zh) * 2015-12-25 2019-06-04 百泰生物药业有限公司 一种抗CD6单抗T1h的检测性抗体及应用
ES2991182T3 (es) 2016-10-21 2024-12-02 Biocon Ltd Un anticuerpo monoclonal y un método de uso para el tratamiento del lupus
MX2020008916A (es) 2018-02-27 2021-02-15 Equillium Inc Anticuerpos anti cd6 para el tratamiento del asma grave.
JP7376564B2 (ja) 2018-06-29 2023-11-08 シティ・オブ・ホープ 特定の自己免疫疾患を治療するためのｃｄ６標的キメラ抗原受容体
JP2022521973A (ja) 2019-02-26 2022-04-13 エクイリウム，インコーポレイテッド 抗ｃｄ６抗体組成物およびループスを処置するための方法
WO2021138454A1 (en) 2019-12-30 2021-07-08 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
KR20240055093A (ko) 2021-09-08 2024-04-26 센트로 데 인뮤놀러지아 모레큘러 과다 염증 반응으로 인한 세포 및 장기 손상 예방을 위한 항-cd6 단일클론항체의 용도
WO2025096685A1 (en) 2023-10-30 2025-05-08 City Of Hope Methods of making and using regulatory t cells for treatment of autoimmune disorders and cancers
CN120005027B (zh) * 2025-04-10 2025-09-23 中国水产科学研究院长江水产研究所 大口黑鲈cd6抗原结合肽、及其单克隆抗体和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0726912A4 (en) * 1993-11-02 2000-08-23 Univ Duke Cd6 ligand
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos

Also Published As

Publication number Publication date
PT807125E (pt) 2005-03-31
CN1175957A (zh) 1998-03-11
WO1997019111A2 (es) 1997-05-29
ATE280783T1 (de) 2004-11-15
EP0807125A2 (en) 1997-11-19
JP4113929B2 (ja) 2008-07-09
DE69633717T2 (de) 2006-02-02
BRPI9607171B1 (pt) 2016-07-19
CU22584A1 (es) 1999-11-03
KR19980701502A (ko) 1998-05-15
EP0807125B1 (en) 2004-10-27
JPH11506017A (ja) 1999-06-02
CA2210751A1 (en) 1997-05-29
KR100533854B1 (ko) 2006-09-20
AU722882B2 (en) 2000-08-10
CN1222540C (zh) 2005-10-12
CA2210751C (en) 2007-01-30
BR9607171A (pt) 1997-11-11
DK0807125T3 (da) 2005-03-14
AU7690596A (en) 1997-06-11
MX9705445A (es) 1998-06-30
WO1997019111A3 (es) 1998-02-12
US6572857B1 (en) 2003-06-03
DE69633717D1 (de) 2004-12-02

Similar Documents

Publication Publication Date Title
ES2231826T3 (es) Anticuerpos monoclonales anti-cd6 para el tratamiento y el diagnostico de la psoriasis.
ES2091684T3 (es) Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
ES2074042T3 (es) Exotoxina recombinante de pseudomonas construccion de una inmunotoxina activa con efectos secundarios menores.
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
ATE354655T1 (de) Humane antikörper gegen ctla-4 und deren verwendungen
EP0671920A4 (en) AN ANTI-IDIOTYPICAL ANTIBODY AND ITS USE IN THE DIAGNOSIS AND THERAPY OF HIV-RELATED DISEASES.
ECSP024352A (es) Nueva composicion farmaceutica
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
DE69533040D1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
UY28170A1 (es) Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.
NO982062L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
ES2084338T3 (es) Anticuerpos recombinantes especificos para el tnf alfa.
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
ATE197592T1 (de) Monoklonaler antikörper gegen cd44v6
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
EA200401081A1 (ru) Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro
ATE258057T1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
FI953565A7 (fi) Uusi antikoagulanttikofaktoriaktiivisuus
AR004326A1 (es) Utilizacion de al menos un antagonista de tnf-alfa, composicion cosmetica, farmaceutica o dermatologica que contiene dicho antagonista y procedimiento detratamiento cosmetico empleando dicho antagonista.
MX9301858A (es) Anticuerpos monoclonales neutralizantes de hiv-humano recombinante para prevencion y tratamiento de infeccion hiv.
MX9305920A (es) Anticuerpos monoclonales reconfigurados, contra un isotipo de inmunoglobulina.
ES2044170T3 (es) Sal de estroncio, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen.